U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  FORM 10-QSB/A


                                   (Mark One)
           [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
         SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED
                                AUGUST 31, 2003.

                                       OR

          [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
         SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM
                        ______________ TO ______________

                        COMMISSION FILE NUMBER: 000-31431


                               US BIODEFENSE, INC.
             (Exact name of registrant as specified in its charter)

                               Utah                       33-0052057
             (State or jurisdiction of incorporation    I.R.S. Employer
                           or organization            Identification No.)

                              13674 E. Valley Blvd.
                             City of Industry 91746
               (Address of principal executive offices) (Zip Code)

                  Registrant's telephone number: (626) 961-8039

                                 Piedmont, Inc.
                           1001 - 17th Street, Suite M
                              Costa Mesa, CA 92626
          (Former Name or Former Address, if Changed Since Last Report)

        Securities registered pursuant to Section 12(b) of the Act: None

           Securities registered pursuant to Section 12(g) of the Act:
                         Common Stock, $0.001 Par Value

         Indicate by check mark whether the Registrant (1) has filed all
           reports required to be filed by Section 13 or 15(d) of the
         Securities Exchange Act of 1934 during the preceding 12 months
         (or for such shorter period that the Registrant was required to
             file such reports), and (2) been subject to such filing
                   requirements for the past 90 days. Yes X No

             As of August 31, 2003, the Registrant had 10,100,932 of
                      common stock issued and outstanding.

           Transitional Small Business Disclosure Format (check one):
                                   Yes No X .

PART I.

ITEM 1.   FINANCIAL STATEMENTS.

                               US Biodefense, Inc.
                            (Formerly Piedmont, Inc.)
                                  BALANCE SHEET
                                 August 31, 2003
                                   (Unaudited)


                                                          Three Months Ended
                                                           August 31, 2003

ASSETS
CURRENT ASSETS:
   Cash                                                       $         0
   Accounts Receivable                                        $
   Other Investments                                          $         0
                                                              -----------
TOTAL CURRENT ASSETS                                          $
ORGANIZATIONAL COSTS, NET                                     $         0
TOTAL ASSETS                                                  $         0
                                                              ===========

LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
   Accounts Payable                                           $         0
TOTAL CURRENT LIABILITIES                                     $         0
LONG-TERM DEBT                                                $         0

STOCKHOLDERS' EQUITY:
Preferred stock, $.001 par value,
   authorized 40,000,000 shares;
   no shares issued
Common stock, $.001 par value
   authorized 100,000,000 shares,
   issued and outstanding at
   August 31, 2003, 10,100,932 shares                         $    10,101

Additional paid in Capital                                    $ 3,793,289
Earnings Accumulated During Development Stage                 $(3,803,390)
                                                              -----------
TOTAL STOCKHOLDERS' EQUITY                                    $         0

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                    $         0
                                                              ===========

See accompanying notes to interim financial statements
<TABLE>
<CAPTION>

                                   US Biodefense, Inc.
                                (Formerly Piedmont, Inc.)
                                 STATEMENT OF OPERATIONS
                              Three Months and Nine Months
                                Ended on August 31, 2003
                                       (Unaudited)

                                        Three Months      Nine Months       For the year
                                           Ended             Ended            Ended
                                       Aug 31, 2003      Aug 31, 2003     Nov 30, 2002
                                       ------------      ------------     -------------
<S>                                    <C>               <C>              <C>
INCOME:

Revenue                                $          0      $          0      $          0
TOTAL INCOME                           $          0      $          0      $          0
                                       ============      ============      ============

EXPENSES:
General, and Administrative            $    147,000      $    147,000      $          0
Amortization                           $          0      $          0      $          0
Total Expenses                         $    147,000      $    147,000                 $
Net Profit/Loss(-) From Operations     $   (147,000)     $   (147,000)                $
Interest Income                        $       --        $          0      $          0
INCOME (LOSS) BEFORE INCOME TAXES      $   (147,000)     $   (147,000)     $          0
Provision for income tax               $          0      $          0      $          0
NET INCOME (LOSS)                      $   (147,000)     $   (147,000)     $          0
                                       ============      ============      ============
NET INCOME (LOSS) PER                  $       0.00      $       0.00      $       0.00
   SHARE-BASIC AND DILUTED
AVERAGE NUMBER OF SHARES OF
   COMMON STOCK OUTSTANDING              10,100,932        10,100,932        10,093,195

See accompanying notes to interim financial statements



                                     US BIODEFENSE, INC.
                                  (Formerly Piedmont, Inc.)
                              STATEMENT OF STOCKHOLDERS' EQUITY
                            Three Months Ended on August 31, 2003
                                         (Unaudited)


                                                                  Additional
                               Preferred      Common Stock        paid-in       Accumulated
                                 Stock      Shares      Amount    capital       loss

Balance, November 30, 1997          0      23,298,985    23,299    3,625,897    (3,649,048)


December 15, 1997, issued                      72,000        72
  for services rendered,
  at par value

December 15, 1997, issued
  for fees to prepare proxy
  statement and to amend
  Articles of Incorporation,
  at par value                             76,000,000     76,000     (76,000)


December 30, 1997, reverse
  stock split, 100-1                      (98,377,119)   (98,377)     98,377

February 6, 1998, issued
  for proposed acquisition
  of Fort Stockton Oil &
  Gas, Inc.                                 8,977,229      8,977     (1,977)

June 9, 1998, issued for
  services rendered                            52,100         52


Net loss, year ended
  November 30, 1998                 0                                               (8,154)
                                  -----   -----------     ------  ----------    -----------
Balance, November 30, 1998          0      10,023,195     10,023   3,646,297    (3,657,202)

December 1, 1998, issued for
  services rendered                         60,000            60

August 19, 1999, issued for
  services rendered                         10,000            10

Net loss, year ended
  November 30, 1999                 0                                                 (325)
                                  -----   -----------     ------  ----------    -----------
Balance, November 30, 1999          0      10,093,195      10,093  3,646,297    (3,657,527)

Net income, year ended
  November 30, 2000                                                                   1,137

Balance, November 30, 2000           0       10,093,195      10,093  3,646,297    (3,656,390)
                                  =====   ============      ======  =========    ===========

Net loss, year ended
  November 30, 2001                  0                                                  -0-
                                  -----   -----------     ------  ----------    -----------

Balance, November 30, 2001           0      10,093,195      10,093  3,646,297    (3,656,390)
                                  =====   ============      ======  =========    ===========

Net loss, year ended
  November 30, 2002                  0                                                  -0-
                                  -----   -------------     ------  ---------    ----------

Balance, November 30, 2002           0      10,093,195      10,093  3,646,297    (3,656,390)
                                  =====   ============      ======  =========    ===========


Net income, quarter ended
  February 28, 2003                                                                     -0-

Balance, February 28, 2003          0       10,093,195     $10,093  3,646,297    (3,656,390)
                                =======    ===========     ======  =========    ===========

May 15, 2003, reverse
  stock split, 100-1                0      (9,992,263)      (9,992)      9,992

Net income, quarter ended
  May 30, 2003                                                                          -0-

Balance, May 30, 2003               0          100,932      $  101   3,656,289    (3,656,390)
                                =======     ==========      ========  =========    ===========

August 11, 2003, issued
    for cancellation
    of debt                                  1,000,000      $1,000    $11,000

August 11, 2003, issued
    for services                             9,000,000      $9,000   $126,000
Net income, quarter ended
  Aug 31, 2003                                                                      (147,000)
Balance, Aug 31, 2003               0       10,100,932     $10,101   3,793,289    (3,803,390)
                                =======    ===========     =======   =========    ===========


See accompanying notes to interim financial statements.
</TABLE>

                           US Biodefense, Inc.
                           (Formerly Piedmont, Inc.)
                      STATEMENTS OF CASH FLOWS
                    Three Months and Nine Months
                       Ended on August 31, 2003
                            (Unaudited)


                             Three Months        Nine Months    For the year
                                 Ended              Ended           Ended
                              Aug 31, 2003      Aug 31, 2003    Nov 30, 2002
                              ------------      ------------    ------------


CASH FLOWS FROM OPERATING
ACTIVITIES:
Net (Loss) Income:                $(147,000)     $(147,000)      $    0
Stock issued for services            12,000         12,000
Decrease (Accts Payable)            (12,000)       (12,000)
Net Cash (Used) In Operating
Activities                       $(147,000)      $(147,000)      $    0

CASH FLOWS FROM INVESTING
ACTIVITIES
Purchase of organizational
Costs                            $  0            $       0       $    0
CASH FLOWS FROM FINANCING
ACTIVITIES
Issuance of common stock for
Cash                             $  0            $       0       $    0

Net Increase in Cash             $(147,000)      $(147,000)      $    0
Cash, Beginning of Period        $  0            $       0       $    0
Cash, End of Period              $  0            $       0       $    0

See accompanying notes to interim financial statements

                               US Biodefense, Inc.
                            (Formerly Piedmont, Inc.)
                          NOTES TO INTERIM CONSOLIDATED
                              FINANCIAL STATEMENTS

NOTE 1 - HISTORY, ACCOUNTING POLICIES AND PROCEDURES

The Company was incorporated June 29, 1983 under the laws of the State of Utah
as Teal Eye, Inc. On September 7, 1984, the Company merged with Terzon Corp. and
amended its Articles of Incorporation changing the Company name to Terzon Corp.
On September 7, 1984, the Company amended its Articles of Incorporation changing
its name to Candy Stripers Candy Corporation, Inc.. On January 6, 1998, the
Company amended its Articles of Incorporation changing its name to Piedmont,
Inc. On May 13, 2003, the Company amended its Articles of Incorporation changing
its name to US Biodefense, Inc.

The nature of the Company's business was the development of websites, including
consultation and design, for the sale of retail products. The company's website
(www.piedmontcybermall.com) is presently operational but will be shut down
shortly. The Company has changed its direction since the change in management
and ownership. The new Board of Directors is interested in developing,
acquiring, and assisting companies in the biodefense industry.

On August 6, 2003, the stockholders approved setting aside 10,000,000 shares of
common stock for an Employee, Directors and Consultants Stock Plan For The Year
2003, which was approved by the Board of Directors on August 6, 2003. On August
8, 2003, the Company filed Form S-8 Registration Statement under the Securities
Act of 1933 for the registration of 10,000,000 shares under the Plan.

The Company has adopted the following accounting policies and procedures:

1. The Company uses the accrual method of accounting.

2. Earnings (loss) per share is calculated using a weighted averaged number of
shares of common stock outstanding.

3. The Company has elected a fiscal year ending November 30th.

NOTE 2 - EMPLOYEE STOCK PLAN

On August 6, 2003, the stockholders approved setting aside 10,000,000 shares of
common stock for an Employee, Directors and Consultants Stock Plan For The Year
2003, which was approved by the Board of Directors on August 6, 2003.

NOTE 3 - WARRANTS AND OPTIONS

There are no warrants or stock options outstanding to acquire any additional
shares of common stock of the Company.

NOTE 4 - STOCKHOLDERS' EQUITY.

Common Stock.

The authorized common stock of US Biodefense, Inc. consists of 100,000,000
shares with a par value of $0.001 per share. As of August 31, 2003, US
Biodefense, Inc. had 10,100,932 shares outstanding.

Preferred Stock.

The authorized Preferred Stock of US Biodefense, Inc. consists of 40,000,000
shares with a par value of $0.001 per share. No preferred shares have been
issued.

NOTE 5 - INCOME TAXES.

There is no provision for income taxes for the period ended August 31, 2003 due
to the losses incurred by the company and substantial loss carry forward.

ITEM 2.  PLAN OF OPERATION.

The following discussion should be read in conjunction with the financial
statements of US Biodefense, Inc. and notes thereto contained elsewhere in this
report.

Initial Operation.

Up to the present time, US Biodefense, Inc. has only been in the organizational
phase. Over the next 12 months US Biodefense, Inc. intends to concentrate its
efforts in development and acquisition of businesses in the biodefense industry.
US Biodefense, Inc. will also be seeking to enhance its revenues by consulting
with businesses in the biodefense industry and related fields.

US Biodefense, Inc. will need to raise additional capital in order to continue
its operations. Such financing will probably take the form of a combination of
debt and equity financing. However, there is no guarantee that such financing
will be available at all or on such terms as will be acceptable to US
Biodefense, Inc.

Currently, US Biodefense, Inc. does not plan to make significant equipment
purchases in the next 12 months in order to implement its plan of operation.
Also, it does not plan over such period to significantly change the number of
employees.

Liquidity and Capital Resources.

During the three month period ended August 31, 2003, US Biodefense, Inc.
continued its status as a development company. US Biodefense, Inc. is continuing
to incur limited development expenses, is deriving no revenues, and has
experienced an ongoing deficiency in working capital. US Biodefense, Inc.'s
continued existence is dependent on its ability to obtain additional financing
to proceed with its plan of operation.

Capital Expenditures.

No material capital expenditures were made during the quarter ended on August
31, 2003.

PART II.

ITEM 1.  LEGAL PROCEEDINGS.

US Biodefense, Inc. is not a party to any material pending legal proceedings
and, to the best of its knowledge, no such action by or against US Biodefense,
Inc. has been threatened.

ITEM 2.  CHANGES IN SECURITIES AND USE OF PROCEEDS.

Not Applicable.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

Not Applicable.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

The Company held a special meeting of shareholders on August 6, 2003, whereby a
majority of the shareholders of the Company approved setting aside 10,000,000
shares of common stock for an Employee, Directors and Consultants Stock Plan For
The Year 2003. The Board of Directors approved the Plan on August 6, 2003, a
copy of which is attached as Exhibit 4 to the Company's Form S-8 filed on August
8, 2003.

ITEM 5.  OTHER INFORMATION.

Not Applicable

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K.

(a)      Reports on Form 8-K.
  During this quarter, the Company filed a Form 8-K on June 9, 2003, reporting
  the change in CPA accountancy firms, the election of David Chin as President,
  Secretary, Treasurer, and Director, and that a majority of the shareholders of
  the Company have elected to effect a reverse stock split whereby one
  post-split share of the Company's $0.001 par value common stock will be issued
  for every 100 pre-split shares of the Company's common stock held by the
  shareholders of the Company. Additionally, the Company has submitted a request
  with Nasdaq Market Integrity to change its ticker symbol.

(b)      Exhibits included or incorporated by reference herein:

     None

SIGNATURE:

                            CERTIFICATION PURSUANT TO
                  SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

       In connection with the Quarterly Report of US Biodefense, Inc. (formerly
Piedmont, Inc.) (the "Registrant") on Form 10-QSB for the quarterly period
ending August 31, 2003 as filed with the Securities and Exchange Commission on
the date hereof (the "Report"), I, David Chin, Chairman of the Board of
Directors, President, and Chief Executive Officer of the Registrant, certify,
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, that:


       1.I have reviewed this quarterly report on Form 10-QSB of the Registrant;


       2. Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this
quarterly report;


       3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
Registrant as of, and for, the periods presented in this quarterly report;


       4. I am responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
Registrant and I have:


          a) designed such disclosure controls and procedures to ensure that
          material information relating to the Registrant, including its
          consolidated subsidiaries, is made known to me by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

          b) evaluated the effectiveness of the Registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the Evaluation Date); and

          c) presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on my
          evaluation as of the Evaluation Date;


        5. I have disclosed, based on our most recent evaluation, to the
Registrant's auditors and the audit committee of Registrant's board of directors
(or persons performing the equivalent function):


          a) all significant deficiencies in the design or operation of internal
          controls which could adversely affect the Registrant's ability to
          record, process, summarize and report financial data and have
          identified for the Registrant's auditors any material weaknesses in
          internal controls; and


          b) any fraud, whether or not material, that involves management or
          other employees who have a significant role in the Registrant's
          internal controls; and


         6. I have indicated in this quarterly report whether or not there were
significant changes in internal controls or in other factors that could
significantly affect internal controls subsequent to the date of our most recent
evaluation, including any corrective actions with regard to significant
deficiencies and material weaknesses.


Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

                                    US Biodefense, Inc.
Dated: November 3, 2003             By:David Chin
                                    ----------------------
                                    David Chin, President



<PAGE>

                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

       In connection with the Quarterly Report of US Biodefense, Inc. (formerly
Piedmont, Inc.) (the "Registrant") on Form 10-QSB for the quarterly period
ending August 31, 2003 as filed with the Securities and Exchange Commission on
the date hereof (the "Report"), I, David Chin, Chief Executive Officer and Chief
Financial Officer of the Registrant, certify, pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

1.   the report fully complies with the requirements of Section 13(a) or 15(d)
     of the Exchange Act; and

2.   the information contained in the report fairly presents, in all material
     respects, the financial condition and results of operations of the issuer;
     and

3.   A signed original of this written statement required by Section 906 has
     been provided to the Registrant and will be retained by the Registrant and
     furnished to the Securities and Exchange Commission or its staff upon
     request.

Pursuant to the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

                                    US Biodefense, Inc.

Dated: November 3, 2003             By:David Chin
                                    ----------------------------
                                    David Chin
                                    Chief Executive Officer,
                                    and Chief Financial Officer